Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company developing conditionally activated therapeutics for cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City.
Key details:
- Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will participate in a fireside chat
- The presentation is set for September 10, 2024, at 11:00 am ET
- A webcast link will be available on the company's investor relations website
- An archived replay will be accessible for approximately 90 days after the event
This conference provides Werewolf Therapeutics an opportunity to showcase its innovative approach to cancer immunotherapy and engage with potential investors.
Werewolf Therapeutics (Nasdaq: HOWL), una compagnia biofarmaceutica che sviluppa terapie attivate condizionatamente per il trattamento del cancro, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento è programmato per il 9-11 settembre 2024, a New York City.
Dettagli principali:
- Daniel J. Hicklin, Ph.D., Presidente e CEO, e Randi Isaacs, M.D., Chief Medical Officer, parteciperanno a una discussione informale
- La presentazione è fissata per il 10 settembre 2024, alle 11:00 ET
- Un link alla diretta streaming sarà disponibile sul sito web delle relazioni con gli investitori della compagnia
- Un replay archiviato sarà accessibile per circa 90 giorni dopo l'evento
Questa conferenza offre a Werewolf Therapeutics l'opportunità di mostrare il suo approccio innovativo all'immunoterapia contro il cancro e di interagire con potenziali investitori.
Werewolf Therapeutics (Nasdaq: HOWL), una empresa biofarmacéutica que desarrolla terapias activadas condicionalmente para el tratamiento del cáncer, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para el 9 al 11 de septiembre de 2024, en la ciudad de Nueva York.
Detalles clave:
- Daniel J. Hicklin, Ph.D., Presidente y CEO, y Randi Isaacs, M.D., Directora Médica, participarán en un chat informal
- La presentación está programada para el 10 de septiembre de 2024, a las 11:00 am ET
- Un enlace a la transmisión en vivo estará disponible en el sitio web de relaciones con inversores de la empresa
- Una repetición archivada estará accesible por aproximadamente 90 días después del evento
Esta conferencia brinda a Werewolf Therapeutics la oportunidad de mostrar su enfoque innovador en la inmunoterapia contra el cáncer y de interactuar con posibles inversores.
Werewolf Therapeutics (Nasdaq: HOWL)은 암 치료를 위한 조건부 활성화 치료제를 개발하는 생명공학 회사로서, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열릴 예정입니다.
주요 세부사항:
- Daniel J. Hicklin 박사, 회장 겸 CEO 및 Randi Isaacs 박사, 최고 의료 책임자가 대화형 세션에 참여할 것입니다.
- 발표는 2024년 9월 10일 오전 11:00 ET로 예정되어 있습니다.
- 회사 투자자 관계 웹사이트에서 웹캐스트 링크가 제공될 것입니다.
- 행사 후 약 90일간 아카이브 재방송을 이용할 수 있습니다.
이 회의는 Werewolf Therapeutics가 암 면역 요법에 대한 혁신적인 접근 방식을 선보이고 잠재 투자자와 교류할 수 있는 기회를 제공합니다.
Werewolf Therapeutics (Nasdaq: HOWL), une entreprise biopharmaceutique développant des thérapies activées de manière conditionnelle pour le traitement du cancer, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024, à New York.
Détails clés :
- Daniel J. Hicklin, Ph.D., Président et CEO, et Randi Isaacs, M.D., Chief Medical Officer, participeront à une discussion informelle.
- La présentation est prévue pour le 10 septembre 2024 à 11h00 ET.
- Un lien vers le webcast sera disponible sur le site des relations investisseurs de l'entreprise.
- Une rediffusion archivée sera accessible pendant environ 90 jours après l'événement.
Cette conférence donne à Werewolf Therapeutics l'opportunité de présenter son approche innovante en immunothérapie contre le cancer et d'interagir avec des investisseurs potentiels.
Werewolf Therapeutics (Nasdaq: HOWL), ein biopharmazeutisches Unternehmen, das bedingt aktivierte Therapeutika zur Behandlung von Krebs entwickelt, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York City statt.
Wichtige Details:
- Daniel J. Hicklin, Ph.D., Präsident und CEO, sowie Randi Isaacs, M.D., Chief Medical Officer, werden an einem informellen Gespräch teilnehmen.
- Die Präsentation ist für den 10. September 2024 um 11:00 Uhr ET vorgesehen.
- Ein Link zur Live-Übertragung wird auf der Website der Investorenbeziehungen des Unternehmens verfügbar sein.
- Eine archivierte Wiederholung wird ungefähr 90 Tage nach der Veranstaltung zugänglich sein.
Diese Konferenz bietet Werewolf Therapeutics die Möglichkeit, ihren innovativen Ansatz zur Krebsimmuntherapie vorzustellen und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 11:00 am ET on September 10, 2024, at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York.
A webcast link for the H.C. Wainwright Conference event will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent.
Investor Contact:
Josh Rappaport
Precision AQ
212.362.1200
josh.rappaport@precisionaq.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
Amanda.sellers@deerfieldgroup.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing Werewolf Therapeutics (HOWL) at the H.C. Wainwright Conference?
Where can I watch the webcast of Werewolf Therapeutics' (HOWL) presentation?
How long will the replay of Werewolf Therapeutics' (HOWL) presentation be available?
What is the focus of Werewolf Therapeutics' (HOWL) research and development?
